Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 1]

ABSTRACT: VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 1]

PROVIDER: PRJNA894165 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22033615.fastq.gz	Fastqsanger.gz
	SRR22033615_1.fastq.gz	Fastqsanger.gz
	SRR22033615_2.fastq.gz	Fastqsanger.gz
	SRR22033616.fastq.gz	Fastqsanger.gz
	SRR22033616_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

Project description:VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

| PRJNA894162 | ENA

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [ChIP-Seq]

Project description:VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [ChIP-Seq]

| PRJNA894166 | ENA

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [ChIP-Seq]

Project description:The transcriptional activity of the TEAD4 trascription factor requires co-activators. In this study we found that the expression of the TEAD coactivator VGLL1 is repressed in estrogen receptor positive breast cancer but upon resistance to endocrine threapies VGLL1 is expressed to high levels. To elucidate the importance of the coactivator VGLL1 in breast cancer cells resistant to endocrine therapies and to identify the VGLL1 target genes, we performed ChIP-seq for VGLL1 in MCF7 breast cancer cells resistant to fulvestrant (FULVR) and ChiP-seq for TEAD4 in FULVR cells and the isogenic MCF7 cells.

2023-12-05 | GSE216525 | GEO

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 3]

Project description:VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 3]

| PRJNA894163 | ENA

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 2]

Project description:VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 2]

| PRJNA894164 | ENA

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 3]

Project description:To investigate the function of VGLL1 in breast cancer and its role in the resistance to endocrine therapies we generated stable MCF7 cells overexpressing VGLL1 using CRISPR/Cas9 Synergistic Activation Mediator (SAM) method (MCF7 ActCas9-VGLL1 cells). MCF7 ActCas9-VGLL1 cells were also cultured in the presence of fulvestrant 100nmM or 1µM to develop fulvestrant resistant cells (MCF7 ActCas9-VGLL1-FULVR) and RNA-seq was performed in the different cell lines.

2023-12-05 | GSE216528 | GEO

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 2]

Project description:To identify VGLL1 target genes we performed RNA-seq following siRNA-mediated VGLL1 downregulation in FULVR cells.

2023-12-05 | GSE216527 | GEO

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [RNA-Seq 1]

Project description:To investigate if the drug verteporfin can inhibit VGLL1 co-transcriptional activity in Fulvestrant resistant breast cancer cells.

2023-12-05 | GSE216526 | GEO

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer

Project description:Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer

| PRJNA815854 | ENA

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-12-05 | GSE216530 | GEO